文献速递特殊人群用药治疗药物监测与药物基因组学抗栓抗凝管理

真实世界中华法林药物基因组学给药的抗凝终点及新给药方案提议

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
PubMed 文献 · Clin Pharmacol Ther · 2016-12-29

研究基于257例接受VKORC1和CYP2C9基因型指导华法林给药的患者,分析不同基因型患者抗凝终点的差异,并推导新的药物基因组学列线图以优化给药。结果显示,携带0、1或≥2个功能降低等位基因的患者达到治疗性INR的时间和前28天治疗范围内时间百分比存在显著差异。

要点

  • 携带0、1或≥2个VKORC1/CYP2C9功能降低等位基因的患者达到治疗性INR的时间分别为7.8±5.8、7.2±4.7和5.4±4.6天(P=0.0004)。
  • 前28天治疗范围内时间百分比分别为22.2%、27.8%和32.2%(P=0.0127)。
  • 对于携带0至1个VKORC1/CYP2C9变异的患者,可能需要更积极的给药以更有效地达到治疗性抗凝。

核心结论

  • 使用现有药物基因组学算法时,VKORC1/CYP2C9功能降低等位基因数目不同的患者抗凝终点存在显著差异。
  • 携带0至1个变异的患者可能需要更积极的给药方案以更高效地达到治疗性抗凝。

研究设计与样本

  • 研究纳入257例接受VKORC1和CYP2C9基因型指导华法林给药的患者,分析基因型相关的抗凝终点差异,并推导新的药物基因组学列线图。

主要发现

  • 携带0、1或≥2个功能降低等位基因的患者达到治疗性INR的时间分别为7.8±5.8、7.2±4.7和5.4±4.6天(P=0.0004)。
  • 前28天治疗范围内时间百分比分别为22.2%、27.8%和32.2%(P=0.0127)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Achieving therapeutic anticoagulation efficiently with warfarin is important to reduce thrombotic and bleeding risks and is influenced by genotype. Utilizing data from a diverse population of 257 patients who received VKORC1 and CYP2C9 genotype-guided warfarin dosing, we aimed to examine genotype-associated differences in anticoagulation endpoints and derive a novel pharmacogenetic nomogram to more optimally dose warfarin. We observed significant differences across patients with 0, 1, or ≥2 reduced-function VKORC1 or CYP2C9 alleles, respectively, in time to achieve therapeutic international normalized ratio (INR) (7.8 ± 5.8, 7.2 ± 4.7, and 5.4 ± 4.6 days, P = 0.0004) and mean percentage of time in therapeutic range in the first 28 days (22.2, 27.8, and 32.2%, P = 0.0127) with use of existing pharmacogenetic algorithms. These data suggest that more aggressive dosing is necessary for patients with 0 to 1 VKORC1/CYP2C9 variants to more efficiently achieve therapeutic anticoagulation. Herein, we provide a novel kinetic/pharmacodynamic-derived dosing nomogram optimized for a heterogeneous patient population.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Arwood MJ, Deng J, Drozda K, et al. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach. Clin Pharmacol Ther. 2016. PMID: 28032893. doi:10.1002/cpt.558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。